Lonza Accelerates DNA-to-IND Programs with New GS Ori‑Go™ Vector Technology: Delivers Tox Material in 2 Months, IND-Ready in as Fast as 6 Months

July 12, 2026

Lonza Press Release Switzerland

Overview

Lonza announced the enhancement of its preclinical development services, featuring the new GS Ori‑Go™ vector technology, to significantly accelerate DNA-to-IND (Investigational New Drug) programs. This enables the delivery of toxicity study materials in just two months and IND-ready packages in as fast as six months. The technology aims to improve productivity and consistency in early-stage biomanufacturing, contributing to reduced lead times in drug development.

In Depth

Key Findings

Lonza has announced a significant acceleration of its DNA-to-IND (Investigational New Drug) programs through enhanced preclinical development services, which now incorporate the innovative GS Ori‑Go™ vector technology. This breakthrough is set to dramatically shorten the development timeline for biopharmaceuticals, compressing the time to market for novel therapeutics.

Technical / Clinical Details

The new GS Ori‑Go™ vector technology is specifically designed to boost productivity and consistency in early-stage biomanufacturing. Through a combination of this optimized vector system and advanced process development, Lonza is now capable of delivering material required for toxicology studies in a mere two months. Furthermore, the complete package for an Investigational New Drug (IND) application can be prepared in as little as six months. This represents a substantial time saving, potentially cutting several months to over a year off traditional development timelines. This rapid turnaround is achieved through efficient generation of engineered cell lines, swift production of high-quality recombinant proteins, and adherence to stringent quality control standards. Such speed allows pharmaceutical companies to advance promising drug candidates into clinical development much faster, thereby mitigating risks associated with the uncertain early development phases.

Background & Context

Biopharmaceutical development is inherently challenged by its complexity and protracted timelines. The period from preclinical development to IND submission is a critical determinant of a new drug’s market entry. Many biotechnology and pharmaceutical companies are actively seeking to accelerate this ‘DNA-to-IND’ phase, relying on CDMO (Contract Development and Manufacturing Organization) partners for advanced expertise and efficient solutions. Lonza’s GS Ori‑Go™ technology directly addresses this industry need, contributing to reduced development times and improved cost-efficiency, particularly in the context of cell and gene therapies and complex biologics development.

Strategic Significance & Outlook

The introduction of Lonza’s GS Ori‑Go™ vector technology marks a significant milestone in the biopharmaceutical development process. It empowers pharmaceutical companies to enhance their R&D pipeline efficiency and deliver innovative therapies to patients more quickly. Accelerating early-stage development will have a profound impact, especially for therapeutics targeting diseases with high unmet medical needs. Lonza aims to further evolve this technology, eventually providing integrated solutions that seamlessly support the journey from DNA to IND submission and beyond to commercial manufacturing. This represents a crucial step in accelerating innovation and growth across the entire biopharmaceutical industry.

Source: https://www.contractpharma.com/live_from_shows/lonza-advances-integrated-dna-to-ind-programs-with-new-gs-ori%E2%80%91go-vector-technology/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.